<DOC>
	<DOCNO>NCT02099747</DOCNO>
	<brief_summary>The null hypothesis difference CR % 3 month arm test alternative difference CR % alpha level .05 assess odds ratio arm yield model .</brief_summary>
	<brief_title>hATG+CsA v hATG+CsA+Eltrombopag SAA</brief_title>
	<detailed_description>This superiority trial aim increase 3 month complete response rate . The sample size calculate hypothesis experimental treatment increase 3 month response rate 21 % ( 3 fold , base 7 % report Scheinberg et al [ 17 ] ) . Under assumption , sample size reject null hypothesis n=96 patient treatment arm , increase 4 % possibly evaluable patient ( total number 200 patient , 100 treatment arm ) . Statistical design sample size calculation : increase 7 % ( control arm ) 21 % ( investigational arm ) 3 month complete response rate ( two-sided binomial test ) ; alpha-error 0.05 ; power 0.8 .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<criteria>1 . Diagnosis severe severe aplastic anemia , define [ 29 ] : At least two follow : Absolute neutrophil count &lt; 0.5 x 109/L ( severe ) &lt; 0.2 x 109/L ( severe ) Platelet count &lt; 20 x 109/L Reticulocyte count &lt; 60 x 109/L Hypocellular bone marrow ( &lt; 30 % cellularity ) , without evidence fibrosis malignant cell 2 . Male female age &gt; 14 year ; 3 . Written inform consent 4 . Willing able comply requirement visit protocol 5 . Understands randomise either treatment arm 6 . Negative pregnancy test woman child bear age 1 . Prior immunosuppressive therapy ATG ( horse rabbit ) lymphocyte deplete agent ( i.e. , alemtuzumab ) 2 . Eligibility sibling allogeneic stem cell transplantation 3 . Evidence myelodysplastic syndrome , define presence myelodysplastic feature , excess blast karyotypic abnormality typical MDS ( accord revise WHO 2008 criterion ) [ 30 ] , , well primitive marrow disease . Patients diagnosis AA cytogenetic abnormality recurrent MDS ( accord revise WHO 2008 criterion ) [ 30 ] include category , eligible study ; patient del ( 20q ) , +8 Y include category , thus eligible study . The list karyotypic abnormality qualify diagnosis MDS list Appendix . 4 . History clinical suspect constitutional aplastic anemia ( i.e . Fanconi Anemia positive DEB/MMC test Dyskeratosis Congenita ) 5 . History malignant tumor active disease within 5 year enrollment , and/or previous chemoradiotherapy 6 . Previous history stem cell transplantation 7 . Treatment cyclosporin A &lt; 2 week enrollment 8 . Treatment GCSF &lt; 2 week enrollment 9 . CMV viremia , define positive PCR pp65 test 10. WHO performance status â‰¥3 11 . Pregnant breast feeding patient 12 . Patients hepatic , renal cardiac failure , life threaten concurrent disease 13 . Patients HIV infection 14 . Patients without social health care assistance 15 . Patients availability horseATG ( ATGAM ) 16 . Participation another clinical trial within 1 month start trial 17 . Patients and/or female partner male patient use highly effective method birth control i.e . intrauterine device ( IUD ) , hormonal ( oral pill , injection , implant ) , tubal ligation partner 's vasectomy 18. subject know hypersensitivity component medication The presence Paroxysmal Nocturnal Hemoglobinuria clone exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Aplastic Anaemia</keyword>
	<keyword>Eltrombopag</keyword>
	<keyword>HATG</keyword>
	<keyword>ATGAM</keyword>
</DOC>